Literature DB >> 24870591

Elevated expression of Cripto-1 correlates with poor prognosis in non-small cell lung cancer.

Chun-Hua Xu1, Zhi-Hong Sheng, Hui-Di Hu, Ke-Ke Hao, Qing-Bo Wang, Li-Ke Yu.   

Abstract

Human Cripto-1 (CR-1) plays an important oncogenic role during tumorigenesis and is overexpressed in a wide range of carcinomas, yet little is known about CR-1 in non-small cell lung cancer (NSCLC). The aims of this study were to detect CR-1 expression in NSCLC and to analyze its association with prognosis of NSCLC patients. The expression of CR-1 messenger RNA (mRNA) and protein in 35 cases of NSCLC and corresponding noncancerous tissue samples was examined by quantitative real-time reverse transcription-polymerase chain reaction (qRT-PCR) and Western blotting. Immunohistochemistry was performed to detect the expression of CR-1 in 128 NSCLC tissues. The expression levels of CR-1 mRNA and protein in NSCLC tissues were significantly higher than those in corresponding noncancerous tissues (P < 0.001). A high level of CR-1 expression was correlated with poor tumor differentiation (P = 0.002), tumor-node-metastasis (TNM) stage (P = 0.004), and lymph node metastasis (P = 0.001). The results of the Kaplan-Meier analysis indicated that a high expression level of CR-1 resulted in a significantly poor prognosis of NSCLC patients. Multivariate Cox regression analysis revealed that CR-1 expression level was an independent prognostic parameter for the overall survival rate of NSCLC patients. Our data suggest that the high expression of CR-1 may play an important role in the progression of NSCLC, and CR-1 expression may offer a valuable marker for predicting the outcome of patients with NSCLC.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24870591     DOI: 10.1007/s13277-014-2039-1

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  23 in total

Review 1.  Cancer screening in the United States, 2009: a review of current American Cancer Society guidelines and issues in cancer screening.

Authors:  Robert A Smith; Vilma Cokkinides; Otis W Brawley
Journal:  CA Cancer J Clin       Date:  2009 Jan-Feb       Impact factor: 508.702

2.  Reactivation of embryonic nodal signaling is associated with tumor progression and promotes the growth of prostate cancer cells.

Authors:  Mitchell G Lawrence; Naira V Margaryan; Daniela Loessner; Angus Collins; Kris M Kerr; Megan Turner; Elisabeth A Seftor; Carson R Stephens; John Lai; Lynne-Marie Postovit; Judith A Clements; Mary J C Hendrix
Journal:  Prostate       Date:  2011-01-12       Impact factor: 4.104

3.  Cripto-1 enhances the canonical Wnt/β-catenin signaling pathway by binding to LRP5 and LRP6 co-receptors.

Authors:  Tadahiro Nagaoka; Hideaki Karasawa; Thomas Turbyville; Maria-Cristina Rangel; Nadia P Castro; Monica Gonzales; Alyson Baker; Masaharu Seno; Stephen Lockett; Yoshimi E Greer; Jeffrey S Rubin; David S Salomon; Caterina Bianco
Journal:  Cell Signal       Date:  2012-09-27       Impact factor: 4.315

4.  Cripto-1 is a cell surface marker for a tumorigenic, undifferentiated subpopulation in human embryonal carcinoma cells.

Authors:  Kazuhide Watanabe; Matthew J Meyer; Luigi Strizzi; Joseph M Lee; Monica Gonzales; Caterina Bianco; Tadahiro Nagaoka; Shahram S Farid; Naira Margaryan; Mary J C Hendrix; Barbara K Vonderhaar; David S Salomon
Journal:  Stem Cells       Date:  2010-08       Impact factor: 6.277

5.  The role of Cripto-1 in the tumorigenesis and progression of oral squamous cell carcinoma.

Authors:  Hye-Jung Yoon; Ji-Soo Hong; Wui-Jung Shin; Yoo-Jin Lee; Kyoung-Ok Hong; Jae-Il Lee; Sam-Pyo Hong; Seong-Doo Hong
Journal:  Oral Oncol       Date:  2011-08-06       Impact factor: 5.337

6.  Pentraxin-3 is a novel biomarker of lung carcinoma.

Authors:  Eleftherios P Diamandis; Lee Goodglick; Chris Planque; Mark D Thornquist
Journal:  Clin Cancer Res       Date:  2011-01-21       Impact factor: 12.531

7.  Regulation of human Cripto-1 expression by nuclear receptors and DNA promoter methylation in human embryonal and breast cancer cells.

Authors:  Caterina Bianco; Nadia P Castro; Christina Baraty; Kelly Rollman; Natalie Held; Maria Cristina Rangel; Hideaki Karasawa; Monica Gonzales; Luigi Strizzi; David S Salomon
Journal:  J Cell Physiol       Date:  2013-06       Impact factor: 6.384

8.  Cripto-1 expression in uveal melanoma: an immunohistochemical study.

Authors:  Kandalam Mallikarjuna; Pushparaj Vaijayanthi; Subramanian Krishnakumar
Journal:  Exp Eye Res       Date:  2007-02-07       Impact factor: 3.467

9.  Autoantibodies against insulin-like growth factor‑binding protein-2 as a serological biomarker in the diagnosis of lung cancer.

Authors:  Ying Zhang; Xia Ying; Suxia Han; Jing Wang; Xia Zhou; E Bai; Jianying Zhang; Qing Zhu
Journal:  Int J Oncol       Date:  2012-11-15       Impact factor: 5.650

10.  Expression and functional role of CRIPTO-1 in cutaneous melanoma.

Authors:  A De Luca; L Lamura; L Strizzi; C Roma; A D'Antonio; N Margaryan; G Pirozzi; M-Y Hsu; G Botti; E Mari; M J C Hendrix; D S Salomon; N Normanno
Journal:  Br J Cancer       Date:  2011-08-23       Impact factor: 7.640

View more
  19 in total

1.  Biochemical and Cellular Analysis Reveals Ligand Binding Specificities, a Molecular Basis for Ligand Recognition, and Membrane Association-dependent Activities of Cripto-1 and Cryptic.

Authors:  Senem Aykul; Anthony Parenti; Kit Yee Chu; Jake Reske; Monique Floer; Amy Ralston; Erik Martinez-Hackert
Journal:  J Biol Chem       Date:  2017-01-26       Impact factor: 5.157

2.  High cripto-1 and low miR-205 expression levels as prognostic markers in early stage non-small cell lung cancer.

Authors:  Kang-Seo Park; Yong Wha Moon; Mark Raffeld; Dae Ho Lee; Yisong Wang; Giuseppe Giaccone
Journal:  Lung Cancer       Date:  2017-12-15       Impact factor: 5.705

3.  Elevated expression of Cripto-1 correlates with poor prognosis in hepatocellular carcinoma.

Authors:  Jia-Hong Wang; Wei Wei; Jing Xu; Zhi-Xing Guo; Cheng-Zuo Xiao; Yong-Fa Zhang; Pei-En Jian; Xiao-Liang Wu; Ming Shi; Rong-Ping Guo
Journal:  Oncotarget       Date:  2015-10-27

4.  Prognostic significance of serum chemerin levels in patients with non-small cell lung cancer.

Authors:  Chun-Hua Xu; Yang Yang; Yu-Chao Wang; Jun Yan; Li-Hua Qian
Journal:  Oncotarget       Date:  2017-04-04

5.  Diagnostic and prognostic value of serum periostin in patients with non-small cell lung cancer.

Authors:  Chun-Hua Xu; Wei Wang; Yong Lin; Li-Hua Qian; Xiu-Wei Zhang; Qing-Bo Wang; Li-Ke Yu
Journal:  Oncotarget       Date:  2017-03-21

Review 6.  TGF-β superfamily co-receptors in cancer.

Authors:  John B Pawlak; Gerard C Blobe
Journal:  Dev Dyn       Date:  2021-04-09       Impact factor: 3.780

7.  The serum activity of thioredoxin reductases 1 (TrxR1) is correlated with the poor prognosis in EGFR wild-type and ALK negative non-small cell lung cancer.

Authors:  Gong Chen; Qiong Chen; Fanxu Zeng; Liang Zeng; Haiyan Yang; Yi Xiong; Chunhua Zhou; Li Liu; Wenjuan Jiang; Nong Yang; Yongchang Zhang
Journal:  Oncotarget       Date:  2017-12-14

8.  Cancer-testis gene PIWIL1 promotes cell proliferation, migration, and invasion in lung adenocarcinoma.

Authors:  Kaipeng Xie; Kai Zhang; Jing Kong; Cheng Wang; Yayun Gu; Cheng Liang; Tingting Jiang; Na Qin; Jibin Liu; Xuejiang Guo; Ran Huo; Mingxi Liu; Hongxia Ma; Juncheng Dai; Zhibin Hu
Journal:  Cancer Med       Date:  2017-11-23       Impact factor: 4.452

9.  Cripto-1 acts as a functional marker of cancer stem-like cells and predicts prognosis of the patients in esophageal squamous cell carcinoma.

Authors:  Qiang Liu; Xiang Cui; Xi Yu; Bai-Shi-Jiao Bian; Feng Qian; Xu-Gang Hu; Cheng-Dong Ji; Lang Yang; Yong Ren; Wei Cui; Xia Zhang; Peng Zhang; Ji Ming Wang; You-Hong Cui; Xiu-Wu Bian
Journal:  Mol Cancer       Date:  2017-04-21       Impact factor: 27.401

10.  Clinical significance of cripto-1 expression in lung adenocarcinoma.

Authors:  Hua Zhang; Bin Zhang; Liuwei Gao; Lianmin Zhang; Kaikai Zhu; Runfen Cheng; Changli Wang
Journal:  Oncotarget       Date:  2017-02-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.